Last updated: February 21, 2026
What is NDC 00115-4433?
NDC 00115-4433 refers to Nivolumab (Opdivo), a monoclonal antibody developed by Bristol-Myers Squibb. Approved for multiple cancer indications, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, it is a key drug in immune checkpoint inhibition.
Market Landscape
Current Market Penetration
Nivolumab has established a leading position in immune checkpoint inhibitors, competing with pembrolizumab (Keytruda), atezolizumab (Tecentriq), and durvalumab (Imfinzi). Its approvals span over 40 indications globally, with revenue generation primarily in oncology segments.
Market Size and Revenue
- Global Oncology Immunotherapy Market (2022): Valued at USD 145 billion, projected to reach USD 220 billion by 2028, with immune checkpoint inhibitors representing a significant share.
- Nivolumab Revenue (2022): Approximately USD 8.7 billion, a 15% increase compared to 2021. Key markets include the US, EU, and Japan.
Competitive Dynamics
| Drug |
Year Approved |
Key Indications |
Revenue (2022) |
Market Share (2022) |
| Nivolumab |
2014 |
Melanoma, lung, kidney, others |
USD 8.7B |
35% |
| Pembrolizumab |
2014 |
Wide indications, including NSCLC |
USD 12B |
45% |
| Atezolizumab |
2016 |
Lung, breast, bladder |
USD 2.5B |
10% |
| Durvalumab |
2017 |
Lung, bladder, head and neck |
USD 1.5B |
6% |
Breakthrough and Pipeline Indicators
- Nivolumab's combination therapies and new indications continue to expand.
- Ongoing trials target earlier-stage cancers and combination regimens with agents like relatlimab, increasing potential growth.
Price Projection and Pricing Trends
Current Pricing Structure
The average wholesale price (AWP) for Nivolumab varies by indication and dose but generally ranges between USD 90,000 to USD 150,000 per year per patient in the US.
| Indication |
Cost per Year (USD) |
Dose Schedule |
| Melanoma |
USD 150,000 |
240 mg IV every 2 weeks |
| NSCLC |
USD 135,000 |
240 mg IV every 2 weeks |
| Renal Cell Carcinoma |
USD 150,000 |
Same as above |
Future Price Trends
- Negotiations and PBMs: U.S. pricing is influenced by rebates, patient assistance programs, and negotiations with payers. Actual net prices may fall 20-30% below list prices.
- Global Market: Pricing varies considerably, with Europe and Asia showing discounts up to 50% compared to US prices.
- Impact of Biosimilars: No biosimilars are currently approved for Nivolumab, but potential entry is expected to drive prices down in the next 3-5 years.
Price Projections (2023–2028)
| Year |
Estimated Average Price (USD) |
Notes |
| 2023 |
USD 125,000–135,000 |
Stable, with minor rebates |
| 2024 |
USD 120,000–130,000 |
Slight decrease expected |
| 2025 |
USD 115,000–125,000 |
Price pressure from payers/global markets |
| 2026 |
USD 110,000–120,000 |
Biosimilars penetration possible |
| 2027 |
USD 105,000–115,000 |
Continued cost decline |
| 2028 |
USD 100,000–110,000 |
Likely biosimilar influence |
Factors Influencing Price Trends
- Regulatory approvals of new indications and combination therapies expand market size.
- Payer negotiations and value-based pricing models influence net prices.
- Biosimilar development may reduce costs but faces regulatory or licensing delays.
Key Market Drivers and Risks
Drivers
- Increase in cancer incidence, especially in aging populations.
- Regulatory approvals extending indications.
- Expansion into early-stage and adjuvant therapy settings.
- Ongoing combination trials with other immuno-oncology agents.
Risks
- Price sensitivity from payers and governments.
- Competition from biosimilars and emerging therapies.
- Slower-than-expected regulatory approvals.
- Patent expirations, notably the original patents expiring in 2028–2030.
Key Takeaways
- Nivolumab sales reached nearly USD 9 billion in 2022, maintaining a dominant position in immuno-oncology.
- Prices vary significantly by geography and payer arrangements, with US list prices around USD 135,000 annually.
- Revenue growth is driven by expanding indications and combination therapies.
- Upcoming biosimilars and patent cliffs may lower prices, particularly by 2028.
- Market expansion into earlier stages of cancer and novel combinations presents growth opportunities.
FAQs
Q1: How does Nivolumab's pricing compare with similar drugs?
A1: It generally costs less than pembrolizumab in similar indications but still exceeds USD 100,000 annually for most treatments.
Q2: What factors could lead to significant price drops?
A2: Biosimilar entry, patent expirations, and increased payer pressure.
Q3: Are there any emerging markets with different price structures?
A3: Yes, Europe and Asia often see discounts between 30-50% compared to US prices.
Q4: What is the typical dosing schedule for Nivolumab?
A4: 240 mg intravenously every two weeks, with some regimens using 480 mg every four weeks.
Q5: What upcoming regulatory approvals could impact the market?
A5: Potential approvals of new indications, combinations, and biosimilars are expected to influence the market.
Sources
[1] Bristol-Myers Squibb, 2022 Annual Report.
[2] IQVIA. (2022). Oncology drug sales data.
[3] GlobalData. (2023). Oncology immunotherapy market forecast.
[4] FDA. (2022). Drug Approvals and Indications.
[5] EvaluatePharma. (2023). Market projections for immune checkpoint inhibitors.
